New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
06:17 EDTBAYRYBayer to acquire Dihon Pharmaceutical Group in China
Bayer plans to acquire 100% of the shares of Dihon Pharmaceutical Group Co., Ltd., Kunming Yunnan, China, a privately held pharmaceutical company specializing primarily in over-the-counter and herbal traditional Chinese medicine products. Dihon is a player in China's OTC industry with products such as Kang Wang for the treatment of dandruff and other scalp disorders and Pi Kang Wang, an antifungal cream, as well as TCM product Dan E Fu Kang for the treatment of various women's health indications. Financial details have not been disclosed. The transaction is subject to fulfillment of certain conditions, including merger control clearance, and is expected to close in the second half of 2014.
News For BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
11:04 EDTBAYRYIsis Pharmaceuticals partnership deal generally expected, says Piper Jaffray
Piper Jaffray noted that Isis Pharmaceuticals (ISIS) had been indicating a high level of interest in its FXIrx anti-clotting antisense program ahead of announcing its deal with Bayer (BAYRY) and the firm believes the announcement of a partnership pact was generally expected. The firm said it already included "meaningful" economics from the FXI program in its valuation for Isis and maintains a Neutral rating on the stock, which is up 4.6% to $60.92 in morning trading.
09:03 EDTBAYRYIsis Pharmaceuticals enters into license agreement with Bayer HealthCare
Subscribe for More Information
07:26 EDTBAYRYWorldwide Business Research to hold a conference
BioNetwork East 2015 Partnering Conference is being held in Miami on May 4-6.
07:12 EDTBAYRYAmerican Congress of Obstetrics and Gynecology
2015 ACOG Annual Clinical & Scientific Meeting is being held in San Francisco on May 2-6.
April 30, 2015
09:36 EDTBAYRYBayer says Xarelto not losing market share to Eliquis, Reuters reports
Bayer (BAYRY) says Xarelto is not losing its U.S. market share to Bristol-Myers' (BMY) Eliquis, reports Reuters. In a conference call, Bayer said that Eliquis was taking business from warfarin and other drugs, but not from Xarelto. Reference Link
05:27 EDTBAYRYBayer sees FY15 sales EUR 48B-EUR 49B
Subscribe for More Information
05:23 EDTBAYRYBayer reports Q1 Healthcare sales up 25.6% to EUR 5.74B
Subscribe for More Information
05:22 EDTBAYRYBayer reports Q1 net income EUR 1.30B vs. EUR 1.42B
Subscribe for More Information
April 22, 2015
12:49 EDTBAYRYEU proposes new law that allows states to ban biotech crops, WSJ reports
Subscribe for More Information
07:07 EDTBAYRYEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use